Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
West Financial Advisors LLC Makes New Investment in Eli Lilly and Company (NYSE:LLY)
West Financial Advisors LLC bought a new position in Eli Lilly and Company (NYSE:LLY – Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission.
Eli Lilly and Company (LLY): Stock That Will Make You Rich in 5-10 Years
We recently compiled a list of the 10 stocks that will make you rich in 5-10 years. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other the Stock That Will Make You Rich in 5-10 Years.
With Its GLP-1 Drugs No Longer in a Shortage, Is Now the Time to Buy Eli Lilly Stock?
While artificial intelligence (AI) has been one of the hottest investing trends, GLP-1 weight loss drugs are a close second. Demand for Eli Lilly's Mounjaro and Zepbound remains robust, and sell-side analysts tracking script data shows strong growth for both of these drugs.
Eli Lilly and Company (NYSE:LLY) Shares Up 2.3% – Here’s What Happened
Eli Lilly and Company (NYSE:LLY – Get Free Report) shares rose 2.3% on Tuesday . The company traded as high as $920.28 and last traded at $918.90. 633,356 shares changed hands during mid-day trading,
Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030
Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 568.82% and currently trading at $884.25. The company has been around since 1876 and the stock didn’t go public until 1952 but in the last 4 years,
Billion-Dollar News for Eli Lilly Stock Investors
Eli Lilly shares have soared thanks to excitement about the company's position in the weight loss drug market.
Eli Lilly and Company (LLY): Hedge Funds Are Bullish On This Momentum Stock Now
Barclays Sticks to Its Buy Rating for Eli Lilly & Co (LLY)
In a report released today, Carter Gould from Barclays maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a
2h
on MSN
Novo and Eli contender Zealand Pharma heralds its obesity drug alternative: It's our 'crown jewel'
Danish biotech Zealand Pharma is targeting the "next generation" of weight loss drugs as competitors pile into a market ...
13h
AG, Eli Lilly spar before the Michigan Supreme Court over insulin pricing investigation
The justices are considering an effort challenging longstanding case law blocking the state’s ability to probe inflated drug ...
16h
Eli Lilly Issues Cease-And-Desist Letters to Compounders Over Weight-Loss Drug Copies As Shortage Resolves
Eli Lilly intensifies its legal efforts against compounding pharmacies producing copycat versions of its weight-loss drugs, ...
16h
Knockoff weight loss drug sellers are fighting back against Eli Lilly and the FDA
Eli Lilly (LLY) is calling on companies that have been selling off-brand versions of its popular diabetes and weight-loss ...
7d
on MSN
Eli Lilly plans $4.5 billion facility in LEAP District, bringing investment to $13 billion
The $4.5 billion investment will create the Lilly Medicine Foundry, a center that will combine research and manufacturing ...
STAT
1d
Eli Lilly, Insitro ink a new kind of AI drug development deal
Machine-learning drug development company Insitro has inked three agreements with Eli Lilly for new medicines for metabolic ...
FiercePharma
2d
Compounders sue FDA for removing Eli Lilly's tirzepatide from shortage list
With an estimated 2 million people in the United States taking copycat vers | A compounding industry group has sued the FDA, ...
FierceBiotech
3d
AstraZeneca pays CSPC $100M for preclinical heart disease drug, teeing up combos and Lilly rivalry
AstraZeneca has paid CSPC Pharmaceutical Group $100 million for a preclinical cardiovascular disease drug candidate. The deal ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback